Consistently, we did not detect any alteration in FLT3L systemic levels in patients with newly diagnosed or chronic IBD, thus suggesting that release of Flt3L is not a hallmark of intestinal inflammation. This evidence concerns the gene FLT3LG and inflammatory bowel disease.